Date: 2013-10-03
Type of information: R&D agreement
Compound: DCOne™ technology for the development of a dendritic cell-based vaccine
Company: DCPrime (The Netherlands) Janssen Pharmaceuticals - J&J (USA)
Therapeutic area: Technology - Services
Type agreement: R&D
licensing
Action mechanism:
Disease:
Details: * On October 3, 2013, DCPrime has entered into a research and optional license agreement with Janssen Pharmaceuticals. The collaboration has been facilitated in conjunction with the Johnson & Johnson London Innovation Centre, where a team of business, science and transaction experts are identifying and building novel early-stage collaborations with emerging companies. Under the agreement, Janssen will utilize DCPrime’s DCOne™ technology in feasibility studies for the development of a dendritic cell-based vaccine. Additionally, Janssen will have the option to further develop a candidate therapeutic towards regulatory approval.
Financial terms:
Latest news:
